-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

Benzinga·08/17/2026 13:22:55
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.